Diffuse large B cell lymphoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== | ==Genetics== | ||
*[[Gene expression profiling]] studies have also attempted to distinguish heterogeneous groups of Diffuse large B cell lymphoma from each other. | *[[Gene expression profiling]] studies have also attempted to distinguish heterogeneous groups of Diffuse large B cell lymphoma from each other. | ||
*These studies examine thousands of genes simultaneously using a [[DNA microarray]], looking for patterns which may help in grouping cases of Diffuse large B cell lymphoma. | *These studies examine thousands of genes simultaneously using a [[DNA microarray]], looking for patterns which may help in grouping cases of Diffuse large B cell lymphoma. | ||
*Many studies now suggest that cases of Diffuse large B cell lymphoma, | *Many studies now suggest that cases of Diffuse large B cell lymphoma,not otherwise specified can be separated into two groups on the basis of their gene expression profiles | ||
:*Germinal centre B-cell-like (GCB) | :*Germinal centre B-cell-like (GCB) | ||
:*Activated B-cell-like (ABC).<ref name="Alizadeh2000" /><ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Wright2003">{{cite journal |doi=10.1073/pnas.1732008100 |pmid=12900505 |pmc=187912 |jstor=3147650 |title=A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma |journal=Proceedings of the National Academy of Sciences |volume=100 |issue=17 |pages=9991–6 |year=2003 |last1=Wright |first1=G. |last2=Tan |first2=B. |last3=Rosenwald |first3=A. |last4=Hurt |first4=E. H. |last5=Wiestner |first5=A. |last6=Staudt |first6=L. M. |bibcode=2003PNAS..100.9991W }}</ref> | :*Activated B-cell-like (ABC).<ref name="Alizadeh2000" /><ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Wright2003">{{cite journal |doi=10.1073/pnas.1732008100 |pmid=12900505 |pmc=187912 |jstor=3147650 |title=A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma |journal=Proceedings of the National Academy of Sciences |volume=100 |issue=17 |pages=9991–6 |year=2003 |last1=Wright |first1=G. |last2=Tan |first2=B. |last3=Rosenwald |first3=A. |last4=Hurt |first4=E. H. |last5=Wiestner |first5=A. |last6=Staudt |first6=L. M. |bibcode=2003PNAS..100.9991W }}</ref> | ||
*Tumour cells in the | *Tumour cells in the Germinal centre B-cell-like subgroup resemble normal B cells in the [[Germinal center|germinal centre]] closely, and are generally associated with a favourable prognosis.<ref name="Gutierrez-Garcia2011">{{cite journal |doi=10.1182/blood-2010-12-322362 |pmid=21441466 |title=Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy |journal=Blood |volume=117 |issue=18 |pages=4836–43 |year=2011 |last1=Gutierrez-Garcia |first1=G. |last2=Cardesa-Salzmann |first2=T. |last3=Climent |first3=F. |last4=Gonzalez-Barca |first4=E. |last5=Mercadal |first5=S. |last6=Mate |first6=J. L. |last7=Sancho |first7=J. M. |last8=Arenillas |first8=L. |last9=Serrano |first9=S. |last10=Escoda |first10=L. |last11=Martinez |first11=S. |last12=Valera |first12=A. |last13=Martinez |first13=A. |last14=Jares |first14=P. |last15=Pinyol |first15=M. |last16=Garcia-Herrera |first16=A. |last17=Martinez-Trillos |first17=A. |last18=Gine |first18=E. |last19=Villamor |first19=N. |last20=Campo |first20=E. |last21=Colomo |first21=L. |last22=Lopez-Guillermo |first22=A. |author23=Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) }}</ref><ref name="Lenz2008">{{cite journal |doi=10.1056/NEJMoa0802885 |pmid=19038878 |title=Stromal Gene Signatures in Large-B-Cell Lymphomas |journal=New England Journal of Medicine |volume=359 |issue=22 |pages=2313–23 |year=2008 |last1=Lenz |first1=G. |last2=Wright |first2=G. |last3=Dave |first3=S.S. |last4=Xiao |first4=W. |last5=Powell |first5=J. |last6=Zhao |first6=H. |last7=Xu |first7=W. |last8=Tan |first8=B. |last9=Goldschmidt |first9=N. |last10=Iqbal |first10=J. |last11=Vose |first11=J. |last12=Bast |first12=M. |last13=Fu |first13=K. |last14=Weisenburger |first14=D.D. |last15=Greiner |first15=T.C. |last16=Armitage |first16=J.O. |last17=Kyle |first17=A. |last18=May |first18=L. |last19=Gascoyne |first19=R.D. |last20=Connors |first20=J.M. |last21=Troen |first21=G. |last22=Holte |first22=H. |last23=Kvaloy |first23=S. |last24=Dierickx |first24=D. |last25=Verhoef |first25=G. |last26=Delabie |first26=J. |last27=Smeland |first27=E.B. |last28=Jares |first28=P. |last29=Martinez |first29=A. |last30=Lopez-Guillermo |first30=A. |display-authors=29 }}</ref> | ||
*Activated B-cell-like tumour cells are associated with a poorer prognosis,<ref name="Lenz2008" /> and derive their name from studies which show the continuous activation of certain pathways normally activated when B cells interact with an [[antigen]]. | *Activated B-cell-like tumour cells are associated with a poorer prognosis,<ref name="Lenz2008" /> and derive their name from studies which show the continuous activation of certain pathways normally activated when B cells interact with an [[antigen]]. | ||
*The [[NF-κB]] pathway, which is normally involved in transforming B cells into [[plasma cells]], is an important example of one such pathway.<ref name="Lenz2010">{{cite journal |doi=10.1056/NEJMra0807082 |pmid=20393178 |title=Aggressive Lymphomas |journal=New England Journal of Medicine |volume=362 |issue=15 |pages=1417–29 |year=2010 |last1=Schwartz |first1=Robert S. |last2=Lenz |first2=Georg |last3=Staudt |first3=Louis M. }}</ref> | *The [[NF-κB]] pathway, which is normally involved in transforming B cells into [[plasma cells]], is an important example of one such pathway.<ref name="Lenz2010">{{cite journal |doi=10.1056/NEJMra0807082 |pmid=20393178 |title=Aggressive Lymphomas |journal=New England Journal of Medicine |volume=362 |issue=15 |pages=1417–29 |year=2010 |last1=Schwartz |first1=Robert S. |last2=Lenz |first2=Georg |last3=Staudt |first3=Louis M. }}</ref> | ||
===MicroRNA expression=== | |||
*Recent gene expression studies is the importance of the cells and microscopic structures interspersed between the malignant B cells within the Diffuse large B cell lymphoma tumor, an area commonly known as the tumour [[Microenvironment (biology)|microenvironment]]. | |||
*The presence of gene expression signatures commonly associated with [[macrophage]]s, T cells, and remodelling of the [[extracellular matrix]] seems to be associated with an improved prognosis and better overall survival.<ref name="Lenz2008" /><ref name="Linderoth2008">{{cite journal |doi=10.1111/j.1365-2141.2008.07037.x |pmid=18419622 |title=Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma |journal=British Journal of Haematology |volume=141 |issue=4 |pages=423–32 |year=2008 |last1=Linderoth |first1=Johan |last2=Edén |first2=Patrik |last3=Ehinger |first3=Mats |last4=Valcich |first4=Jeanette |last5=Jerkeman |first5=Mats |last6=Bendahl |first6=Pär-Ola |last7=Berglund |first7=Mattias |last8=Enblad |first8=Gunilla |last9=Erlanson |first9=Martin |last10=Roos |first10=Göran |last11=Cavallin-Ståhl |first11=Eva }}</ref> | |||
*Alternatively, expression of genes coding for [[Angiogenesis|pro-angiogenic]] factors is correlated with poorer survival.<ref name="Lenz2008" /> | |||
Recently, it was described that short non-coding RNAs named microRNAs (miRNAs) have important functions in lymphoma biology. | |||
In malignant B cells miRNAs participate in pathways fundamental to B cell development like | |||
*B cell receptor (BCR) signalling | |||
*B cell migration/adhesion | |||
*Cell-cell interactions in immune niches | |||
*Production and class-switching of immunoglobulins.<ref name="pmid25541152">{{cite journal |doi=10.1038/leu.2014.351 |title=MicroRNAs in B-cell lymphomas: How a complex biology gets more complex |journal=Leukemia |year=2015 |last1=Musilova |first1=K |last2=Mraz |first2=M }}</ref> | |||
MiRNAs influence B cell maturation, generation of pre-, marginal zone, follicular, B1, plasma and [[memory B cell]]s.<ref name="pmid25541152"/> | |||
==Microscopic Pathology== | ==Microscopic Pathology== | ||
Revision as of 22:54, 20 August 2015
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma pathophysiology |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Genetics
- Gene expression profiling studies have also attempted to distinguish heterogeneous groups of Diffuse large B cell lymphoma from each other.
- These studies examine thousands of genes simultaneously using a DNA microarray, looking for patterns which may help in grouping cases of Diffuse large B cell lymphoma.
- Many studies now suggest that cases of Diffuse large B cell lymphoma,not otherwise specified can be separated into two groups on the basis of their gene expression profiles
- Tumour cells in the Germinal centre B-cell-like subgroup resemble normal B cells in the germinal centre closely, and are generally associated with a favourable prognosis.[5][6]
- Activated B-cell-like tumour cells are associated with a poorer prognosis,[6] and derive their name from studies which show the continuous activation of certain pathways normally activated when B cells interact with an antigen.
- The NF-κB pathway, which is normally involved in transforming B cells into plasma cells, is an important example of one such pathway.[7]
MicroRNA expression
- Recent gene expression studies is the importance of the cells and microscopic structures interspersed between the malignant B cells within the Diffuse large B cell lymphoma tumor, an area commonly known as the tumour microenvironment.
- The presence of gene expression signatures commonly associated with macrophages, T cells, and remodelling of the extracellular matrix seems to be associated with an improved prognosis and better overall survival.[6][8]
- Alternatively, expression of genes coding for pro-angiogenic factors is correlated with poorer survival.[6]
Recently, it was described that short non-coding RNAs named microRNAs (miRNAs) have important functions in lymphoma biology.
In malignant B cells miRNAs participate in pathways fundamental to B cell development like
- B cell receptor (BCR) signalling
- B cell migration/adhesion
- Cell-cell interactions in immune niches
- Production and class-switching of immunoglobulins.[9]
MiRNAs influence B cell maturation, generation of pre-, marginal zone, follicular, B1, plasma and memory B cells.[9]
Microscopic Pathology
- Three variants are most commonly seen: centroblastic, immunoblastic, and anaplastic.
Centroblastic
- Most cases of are Diffuse large B cell lymphoma centroblastic, having the appearance of medium-to-large-sized lymphocytes with scanty cytoplasm.
- Oval or round nuclei containing fine chromatin are prominently visible, having two to four nucleoli within each nucleus.
- Sometimes the tumour may be monomorphic, composed almost entirely of centroblasts.
- However, most cases are polymorphic, with a mixture of centroblastic and immunoblastic cells.
Immunoblastic
- Immunoblasts have significant basophilic cytoplasm and a central nucleolus.
- A tumour can be classified as immunoblastic if greater than 90% of its cells are immunoblasts. This distinction can be problematic, however, because hematopathologists reviewing the microscope slides may often disagree on whether a collection of cells is best characterized as centroblasts or immunoblasts.[10] Such disagreement indicates poor inter-rater reliability.
Anaplastic
- The third morphologic variant, anaplastic, consists of tumour cells which appear very differently from their normal B cell counterparts.
- The cells are generally very large with a round, oval, or polygonal shape and pleomorphic nuclei, and may resemble Hodgkin cells or Reed-Sternberg cells.
References
- ↑ Invalid
<ref>tag; no text was provided for refs namedAlizadeh2000 - ↑ Shipp, Margaret A.; Ross, Ken N.; Tamayo, Pablo; Weng, Andrew P.; Kutok, Jeffery L.; Aguiar, Ricardo C.T.; Gaasenbeek, Michelle; Angelo, Michael; Reich, Michael; Pinkus, Geraldine S.; Ray, Tane S.; Koval, Margaret A.; Last, Kim W.; Norton, Andrew; Lister, T. Andrew; Mesirov, Jill; Neuberg, Donna S.; Lander, Eric S.; Aster, Jon C.; Golub, Todd R. (2002). "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning". Nature Medicine. 8 (1): 68–74. doi:10.1038/nm0102-68. PMID 11786909.
- ↑ Rosenwald, Andreas; Wright, George; Chan, Wing C.; Connors, Joseph M.; Campo, Elias; Fisher, Richard I.; Gascoyne, Randy D.; Muller-Hermelink, H. Konrad; Smeland, Erlend B.; Giltnane, Jena M.; Hurt, Elaine M.; Zhao, Hong; Averett, Lauren; Yang, Liming; Wilson, Wyndham H.; Jaffe, Elaine S.; Simon, Richard; Klausner, Richard D.; Powell, John; Duffey, Patricia L.; Longo, Dan L.; Greiner, Timothy C.; Weisenburger, Dennis D.; Sanger, Warren G.; Dave, Bhavana J.; Lynch, James C.; Vose, Julie; Armitage, James O.; Montserrat, Emilio; et al. (2002). "The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma". New England Journal of Medicine. 346 (25): 1937–47. doi:10.1056/NEJMoa012914. PMID 12075054.
- ↑ Wright, G.; Tan, B.; Rosenwald, A.; Hurt, E. H.; Wiestner, A.; Staudt, L. M. (2003). "A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma". Proceedings of the National Academy of Sciences. 100 (17): 9991–6. Bibcode:2003PNAS..100.9991W. doi:10.1073/pnas.1732008100. JSTOR 3147650. PMC 187912. PMID 12900505.
- ↑ Gutierrez-Garcia, G.; Cardesa-Salzmann, T.; Climent, F.; Gonzalez-Barca, E.; Mercadal, S.; Mate, J. L.; Sancho, J. M.; Arenillas, L.; Serrano, S.; Escoda, L.; Martinez, S.; Valera, A.; Martinez, A.; Jares, P.; Pinyol, M.; Garcia-Herrera, A.; Martinez-Trillos, A.; Gine, E.; Villamor, N.; Campo, E.; Colomo, L.; Lopez-Guillermo, A.; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) (2011). "Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy". Blood. 117 (18): 4836–43. doi:10.1182/blood-2010-12-322362. PMID 21441466.
- ↑ 6.0 6.1 6.2 6.3 Lenz, G.; Wright, G.; Dave, S.S.; Xiao, W.; Powell, J.; Zhao, H.; Xu, W.; Tan, B.; Goldschmidt, N.; Iqbal, J.; Vose, J.; Bast, M.; Fu, K.; Weisenburger, D.D.; Greiner, T.C.; Armitage, J.O.; Kyle, A.; May, L.; Gascoyne, R.D.; Connors, J.M.; Troen, G.; Holte, H.; Kvaloy, S.; Dierickx, D.; Verhoef, G.; Delabie, J.; Smeland, E.B.; Jares, P.; Martinez, A.; et al. (2008). "Stromal Gene Signatures in Large-B-Cell Lymphomas". New England Journal of Medicine. 359 (22): 2313–23. doi:10.1056/NEJMoa0802885. PMID 19038878.
- ↑ Schwartz, Robert S.; Lenz, Georg; Staudt, Louis M. (2010). "Aggressive Lymphomas". New England Journal of Medicine. 362 (15): 1417–29. doi:10.1056/NEJMra0807082. PMID 20393178.
- ↑ Linderoth, Johan; Edén, Patrik; Ehinger, Mats; Valcich, Jeanette; Jerkeman, Mats; Bendahl, Pär-Ola; Berglund, Mattias; Enblad, Gunilla; Erlanson, Martin; Roos, Göran; Cavallin-Ståhl, Eva (2008). "Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma". British Journal of Haematology. 141 (4): 423–32. doi:10.1111/j.1365-2141.2008.07037.x. PMID 18419622.
- ↑ 9.0 9.1 Musilova, K; Mraz, M (2015). "MicroRNAs in B-cell lymphomas: How a complex biology gets more complex". Leukemia. doi:10.1038/leu.2014.351.
- ↑ Harris, N. L.; Jaffe, E. S.; Stein, H; Banks, P. M.; Chan, J. K.; Cleary, M. L.; Delsol, G; De Wolf-Peeters, C; Falini, B; Gatter, K. C. (1994). "A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group". Blood. 84 (5): 1361–92. PMID 8068936.